MANAGEMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF UNKNOWN ORIGIN - A SOUTHWEST ONCOLOGY GROUP-STUDY

  • 1 January 1983
    • journal article
    • research article
    • Vol. 67  (1) , 77-79
Abstract
The Southwest Oncology Group evaluated 51 patients with a histologic diagnosis of metastatic adenocarcinoma and an occult primary tumor. Even though all patients received an extensive diagnostic evaluation, only 6 (12%) primary sites were found. Thirty-six patients whose primary tumor sites remained occult were randomized to receive 5-FU [5-fluorouracil] or combination chemotherapy (5-FU, doxorubicin and cyclophosphamide [FAC]). There were no responses in either group. The median survival with 5-FU was 105 days; with FAC it was 95 days. Toxicity with FAC was more common and more severe.